Sectors
EWTX
Edgewise Therapeutics, Inc.
41.20
1 x 41.24
2 x 55.04
bid
ask
-
1.56
3.65%
10:29 AM
timesize
| Ytd | 66.00% | |
| 1y | 187.11% |
41.04
day range
42.46
13.69
52 week range
48.40
| Open | 42.45 | Prev Close | 42.76 | Low | 41.04 | High | 42.46 | Mkt Cap | 4.47B |
| Vol | 112.22K | Avg Vol | 1.44M | EPS | -1.85 | P/E | N/A | Forward P/E | -23.54 |
| Beta | 0.30 | Short Ratio | 8.41 | Inst. Own | 111.84% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 41.94 | 200-d Avg | 32.47 | 1yr Est | 51.69 |
| Income Statement | |||
| Operating Expenses | 61.94M | ||
| Research and Development Expense | 47.55M | ||
| Selling, General and Administrative Expense | 14.40M | ||
| Operating Income | -61.94M | ||
| Net Income | -57.33M | ||
| Net Income Common Stock | -57.33M | ||
| Net Income Common Stock (USD) | -57.33M | ||
| Consolidated Income | -57.33M | ||
| Earnings per Basic Share | -0.53 | ||
| Earnings per Basic Share (USD) | -0.53 | ||
| Earnings per Diluted Share | -0.53 | ||
| Earning Before Interest & Taxes (EBIT) | -57.33M | ||
| Earning Before Interest & Taxes (USD) | -57.33M | ||
| Weighted Average Shares | 107.67M | ||
| Weighted Average Shares Diluted | 107.67M | ||
| Balance Sheet | |||
| Cash and Equivalents | 72.32M | ||
| Cash and Equivalents (USD) | 72.32M | ||
| Investments | 388.39M | ||
| Investments Current | 388.39M | ||
| Current Assets | 471.52M | ||
| Property, Plant & Equipment Net | 8.17M | ||
| Total Assets | 479.69M | ||
| Debt Current | 1.02M | ||
| Total Debt | 3.59M | ||
| Current Liabilities | 29.04M | ||
| Debt Non-Current | 2.57M | ||
| Total Liabilities | 31.61M | ||
| Accumulated Retained Earnings (Deficit) | -652.71M | ||
| Accumulated Other Comprehensive Income | -500.00K | ||
| Shareholders Equity | 448.08M | ||
| Shareholders Equity (USD) | 448.08M | ||
| Assets Non-Current | 8.17M | ||
| Total Debt (USD) | 3.59M | ||
| Liabilities Non-Current | 2.57M | ||
| Trade and Non-Trade Payables | 4.67M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 597.00K | ||
| Net Cash Flow from Financing | 3.09M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 39.11M | ||
| Capital Expenditure | -32.00K | ||
| Issuance (Purchase) of Equity Shares | 3.09M | ||
| Net Cash Flow from Investing | 78.49M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 78.52M | ||
| Net Cash Flow from Operations | -42.47M | ||
| Share Based Compensation | 9.36M | ||